PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV is a biopharmaceutical company dedicated to developing therapies for rare genetic diseases.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying PROQR Therapeutics stock with a target price of $7.93, indicating strong growth potential.
Financial Health
PROQR Therapeutics has modest revenue and cash flow, but its financial indicators suggest average performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PRQR
Beyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
RNA Therapy Platform
ProQR’s RNA-based approach aims to correct gene expression, a promising scientific route, though clinical success is uncertain and outcomes can vary.
Catalysts To Watch
Clinical readouts, regulatory updates and partnership deals can materially affect value; such events often drive sharp share-price moves.
Risk And Opportunity
Small-cap biotech investing can offer high upside if trials succeed, but carries higher regulatory, commercial and financing risks — suitability depends on investor risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
